This randomized controlled trial from Ain Shams University investigated the early initiation of dapagliflozin in non-diabetic patients presenting with acute myocardial infarction following successful PCI. While the therapy did not significantly reduce 6-month major adverse cardiovascular events, the dapagliflozin group demonstrated meaningful improvements in cardiac remodeling and functional recovery. Enhancements in LVEF, global longitudinal strain, and reductions in LV volumes were consistently superior to standard therapy alone, with hypertensive and CKD subgroups showing even more pronounced benefits.
These findings reinforce the cardioprotective potential of SGLT2 inhibition independent of glycemic status and highlight its emerging role in early post-MI management. The study provides compelling evidence that dapagliflozin may help reshape myocardial recovery trajectories after AMI.…
